X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/01/2855473/0/en/G1-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com//news-release/2024/03/01/2839075/0/en/G1-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://endpts.com/g1-therapeutics-stock-sinks-nearly-40-on-phiii-readout-delay/
https://www.globenewswire.com//news-release/2024/01/08/2805234/0/en/G1-Therapeutics-Provides-Corporate-Update-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2024/01/02/2802960/0/en/G1-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2023/12/05/2791050/0/en/G1-Therapeutics-Presents-New-Post-Hoc-Analyses-Indicating-That-Patients-Who-Previously-Received-Trilaciclib-Have-Improved-Overall-Survival-with-Subsequent-Anticancer-Therapy.html
https://www.globenewswire.com//news-release/2023/11/30/2788182/0/en/G1-Therapeutics-Announces-Upcoming-Presentation-at-the-2023-San-Antonio-Breast-Cancer-Symposium.html
https://www.globenewswire.com//news-release/2023/11/01/2770927/0/en/G1-Therapeutics-Provides-Third-Quarter-2023-Financial-Results-and-Operational-Highlights.html
https://www.globenewswire.com//news-release/2023/10/27/2768288/0/en/Real-World-Data-Indicate-That-Trilaciclib-Reduces-Hospitalizations-and-Myelosuppressive-Events-and-May-Improve-Survival-in-Patients-with-Extensive-Stage-Small-Cell-Lung-Cancer-ES-S.html
https://www.globenewswire.com//news-release/2023/10/18/2762334/0/en/G1-Therapeutics-COSELA-trilaciclib-Recommended-in-Updated-Small-Cell-Lung-Cancer-Guidelines-from-the-American-Society-of-Clinical-Oncology-ASCO.html
Market Place
Share 
